Roche Holding AG joined rival Sanofi with a setback in the development of an oral selective estrogen receptor degrader (SERD) for locally advanced or metastatic ER-positive/HER2-negative breast cancer, giving an edge to underdog Menarini Group, which remains the only drug maker to have a successful Phase III trial in the setting.
Roche's SERD Setback Means Menarini Retains An Edge
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.
More from Anticancer
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.